Skip to main content
OpenTrials

Clinical trial condition

HER2-negative Breast Cancer

Explore clinical trials studying HER2-negative Breast Cancer. Study availability and eligibility vary by location and protocol.

108 public trials 55 recruiting studies
Refine in advanced search Browse all conditions

HER2-negative Breast Cancer trial results

Recruiting

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

NCT06120283

Conditions
Advanced Breast Cancer, Advanced Solid Tumor, Breast Diseases, +20 more
Locations
  • Sarah Cannon Research Institute (Scri) At Health One Denver, Colorado, United States
  • Florida Cancer Specialists and Research Institute Lake Mary, Florida, United States
  • Karmanos Cancer Institute Detroit, Michigan, United States
  • Washington University School of Medicine St Louis, Missouri, United States
View all 62 locations
View Trial Details
Recruiting

Real-world Study of SKB264 Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer

NCT06993506

Conditions
Disease Attributes, HER2-negative Breast Cancer, Metastasis, +6 more
Locations
  • Cancer Hospital, Chinese Academy of Medical Sciences Beijing, Beijing Municipality, China
  • The Second Affiliated Hospital of Anhui Medical University Hefei, Anhui, China
  • Peking University First Hospital Beijing, Beijing Municipality, China
  • Chinese PLA General Hospital Beijing, Beijing Municipality, China
View all 19 locations
View Trial Details
Recruiting

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

NCT04585750

Conditions
Adnexal Diseases, Advanced Malignant Neoplasm, Advanced Solid Tumor, +81 more
Locations
  • University of California Irvine Chao Family Comprehensive Cancer Center Irvine, California, United States
  • University of San Diego Moores Cancer Center La Jolla, California, United States
  • UCLA Jonsson Comprehensive Cancer Center Los Angeles, California, United States
  • USC Norris Comprehensive Cancer Center Los Angeles, California, United States
View all 77 locations
View Trial Details
Recruiting

Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)

NCT05512364

Conditions
Breast Diseases, Breast Neoplasms, ER-positive Breast Cancer, +7 more
Locations
  • Institut Jules Bordet Anderlecht, Belgium
  • Cliniques Universitaires Saint-Luc Brussels, Belgium
  • Hopital Universitaire Brugmann Brussels, Belgium
  • Grand Hopital de Charleroi - Site Notre Dame Charleroi, Belgium
View all 111 locations
View Trial Details
Recruiting

Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment

NCT07281833

Conditions
Advanced Breast Cancer, Breast Cancer, Breast Diseases, +14 more
Locations
  • Institut Jules Bordet Anderlecht, Belgium
  • St. Elisabeth-Krankenhaus GmbH, Brustzentrum - Senologie Cologne, North Rhine-Westphalia, Germany
  • Universitätsklinikum Essen Essen, North Rhine-Westphalia, Germany
  • Brustzentrum Niederrhein, Johanniter Bethesda Krankenhaus Mönchengladbach, North Rhine-Westphalia, Germany
View all 16 locations
View Trial Details
Recruiting

Sacituzumab Govitecan In TNBC

NCT04230109

Conditions
Breast Diseases, Breast Neoplasms, ER-negative Breast Cancer, +9 more
Locations
  • Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Massachusetts General Hospital - North Shore Cancer Center Danvers, Massachusetts, United States
View Trial Details
Recruiting

Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer

NCT05467891

Conditions
HER2-negative Breast Cancer, Hormone Receptor-Positive Breast Cancer, Locoregional Recurrence
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • University of Arizona Phoenix, Arizona, United States
  • Georgetown University Washington D.C., District of Columbia, United States
  • Orlando Health Cancer Institute Orlando, Florida, United States
View all 21 locations
View Trial Details

Related conditions